Over the last two decades the heady expectations of a genomic revolution in biomedicine have been accompanied by much debate about whether the regulatory regimes that govern diagnostic tests are sufficiently robust to cope with the challenges that this brave new era might present. A persistent concern has been the pace of innovation and the paucity of the evidence base to inform clinical adoption of new genetic tests.